2023-08-17 18:14:27
French researchers have discovered that the absence of a protein in the nucleus of the patient’s tumor cells could render tamoxifen ineffective, thus opening the way to new avenues of treatment.
Rooted in hormonal dysfunction, the hormone-dependent breast cancer is partly treated with hormonal therapies. Tamoxifen, a drug that blocks the action of estrogen, is one of the mainstays of these hormone therapies. This is the reference treatment, the gold standard as the Anglo-Saxons say. About 30% of patients on tamoxifen, however, experience a relapse and die following the development of metastases, sometimes several years after being treated. These dramatic consequences have led researchers to redouble their efforts to try to understand the mechanisms of this ” résistance to tamoxifen. The missing link? It would be a protein expressed in tumor cells, whose mode of action has just been clarified by researchers at the Léon-Bérard cancer center in Lyon.
Named PRMT5, this protein has been the subject of growing interest over the past ten years…
This article is for subscribers only. You have 78% left to discover.
Want to read more?
Unlock all items immediately.
Already subscribed? Login
#promising #avenue #limiting #resistance #tamoxifen